Nucleic acid ligands with protein-like side chains: Modified aptamers and their use as diagnostic and therapeutic agents

Molecular Therapy Nucleic Acids

Volumn 3, Issue , 2014, Pages e201-

  Rohloff, John C ^a   Gelinas, Amy D ^a   Jarvis, Thale C ^a   Ochsner, Urs A ^a   Schneider, Daniel J ^a   Gold, Larry ^a   Janjic, Nebojsa ^a  

^a SomaLogic Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; BIOLOGICAL MARKER; CD3 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIAGNOSTIC AGENT; DNA; ENZYME; FRACTALKINE; GLYCOPROTEIN GP 130; GROWTH FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; HORMONE; INTERLEUKIN 6; LIGAND; MONOCLONAL ANTIBODY; NUCLEASE; NUCLEIC ACID; OLIGONUCLEOTIDE; OSTEOPROTEGERIN; P CADHERIN; PEGAPTANIB; PEGNIVACOGIN; PEGPLERANIB; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN;

AGING; ALZHEIMER DISEASE; BINDING AFFINITY; CANCER CELL; CHRONIC KIDNEY DISEASE; COMBINATORIAL CHEMISTRY; CRYSTAL STRUCTURE; DNA LIBRARY; HUMAN; HYDROGEN BOND; LUNG TUBERCULOSIS; MACROMOLECULE; MESOTHELIOMA; MOLECULARLY TARGETED THERAPY; MOLECULE; NON SMALL CELL LUNG CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

EID: 84924236762     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2014.49     Document Type: Review

References (130)

1. Tuerk, C and Gold, L (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510.
2. Ellington, AD and Szostak, JW (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
3. Gold, L, Brown, D, He, Y, Shtatland, T, Singer, BS and Wu, Y (1997). From oligonucleotide shapes to genomic SELEX: novel biological regulatory loops. Proc Natl Acad Sci USA 94: 59-64.
4. Gold, L, Polisky, B, Uhlenbeck, O and Yarus, M (1995). Diversity of oligonucleotide functions. Annu Rev Biochem 64: 763-797.
5. Cerchia, L, Giangrande, PH, McNamara, JO and de Franciscis, V (2009). Cell-specific aptamers for targeted therapies. Methods Mol Biol 535: 59-78.
6. Esposito, CL, Catuogno, S, de Franciscis, V and Cerchia, L (2011). New insight into clinical development of nucleic acid aptamers. Discov Med 11: 487-496.
7. Shamah, SM, Healy, JM and Cload, ST (2008). Complex target SELEX. Acc Chem Res 41: 130-138.
8. Ohuchi, S (2012). Cell-SELEX technology. Biores Open Access 1: 265-272.
9. Bullock, TL, Sherlin, LD and Perona, JJ (2000). Tertiary core rearrangements in a tight binding transfer RNA aptamer. Nat Struct Biol 7: 497-504.
10. Cheung, YW, Kwok, J, Law, AW, Watt, RM, Kotaka, M and Tanner, JA (2013). Structural basis for discriminatory recognition of Plasmodium lactate dehydrogenase by a DNA aptamer. Proc Natl Acad Sci USA 110: 15967-15972.
11. Convery, MA, Rowsell, S, Stonehouse, NJ, Ellington, AD, Hirao, I, Murray, JB et al. (1998). Crystal structure of an RNA aptamer-protein complex at 2.8 A resolution. Nat Struct Biol 5: 133-139.
12. Huang, DB, Vu, D, Cassiday, LA, Zimmerman, JM, Maher, LJ 3rd and Ghosh, G (2003). Crystal structure of NF-kappaB (p50)2 complexed to a high-affinity RNA aptamer. Proc Natl Acad Sci USA 100: 9268-9273.
13. Huang, RH, Fremont, DH, Diener, JL, Schaub, RG and Sadler, JE (2009). A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1. Structure 17: 1476-1484.
14. Miyakawa, S, Nomura, Y, Sakamoto, T, Yamaguchi, Y, Kato, K, Yamazaki, S et al. (2008). Structural and molecular basis for hyperspecificity of RNA aptamer to human immunoglobulin G. RNA 14: 1154-1163.
15. Nomura, Y, Sugiyama, S, Sakamoto, T, Miyakawa, S, Adachi, H, Takano, K et al. (2010). Conformational plasticity of RNA for target recognition as revealed by the 2.15 A crystal structure of a human IgG-aptamer complex. Nucleic Acids Res 38: 7822-7829.
16. Padlan, CS, Malashkevich, VN, Almo, SC, Levy, M, Brenowitz, M and Girvin, ME (2014). An RNA aptamer possessing a novel monovalent cation-mediated fold inhibits lysozyme catalysis by inhibiting the binding of long natural substrates. RNA 20: 447-461.
17. Pagano, B, Martino, L, Randazzo, A and Giancola, C (2008). Stability and binding properties of a modified thrombin binding aptamer. Biophys J 94: 562-569.
18. Russo Krauss, I, Merlino, A, Giancola, C, Randazzo, A, Mazzarella, L and Sica, F (2011). Thrombin-aptamer recognition: a revealed ambiguity. Nucleic Acids Res 39: 7858-7867.
19. Schultze, P, Macaya, RF and Feigon, J (1994). Three-dimensional solution structure of the thrombin-binding DNA aptamer d(GGTTGGTGTGGTTGG). J Mol Biol 235: 1532-1547.
20. Talbot, SJ, Goodman, S, Bates, SR, Fishwick, CW and Stockley, PG (1990). Use of synthetic oligoribonucleotides to probe RNA-protein interactions in the MS2 translational operator complex. Nucleic Acids Res 18: 3521-3528.
21. Flinders, J, DeFina, SC, Brackett, DM, Baugh, C, Wilson, C and Dieckmann, T (2004). Recognition of planar and nonplanar ligands in the malachite green-RNA aptamer complex. Chembiochem 5: 62-72.
22. Jiang, F, Kumar, RA, Jones, RA and Patel, DJ (1996). Structural basis of RNA folding and recognition in an AMP-RNA aptamer complex. Nature 382: 183-186.
23. Robertson, SA, Harada, K, Frankel, AD and Wemmer, DE (2000). Structure determination and binding kinetics of a DNA aptamer-argininamide complex. Biochemistry 39: 946-954.
24. Sussman, D, Nix, JC and Wilson, C (2000). The structural basis for molecular recognition by the vitamin B 12 RNA aptamer. Nat Struct Biol 7: 53-57.
25. Tereshko, V, Skripkin, E and Patel, DJ (2003). Encapsulating streptomycin within a small 40-mer RNA. Chem Biol 10: 175-187.
26. Hobbs, J, Sternbach, H, Sprinzl, M and Eckstein, F (1973). Polynucleotides containing 2'-amino-2'-deoxyribose and 2'-azido-2'-deoxyribose. Biochemistry 12: 5138-5145.
27. Janik, B, Kotick, MP, Kreiser, TH, Reverman, LF, Sommer, RG and Wilson, DP (1972). Synthesis and properties of poly 2'-fluoro-2'-deoxyuridylic acid. Biochem Biophys Res Commun 46: 1153-1160.
28. Pieken, WA, Olsen, DB, Benseler, F, Aurup, H and Eckstein, F (1991). Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. Science 253: 314-317.
29. Eaton, BE and Pieken, WA (1995). Ribonucleosides and RNA. Annu Rev Biochem 64: 837-863.
30. Fitzwater, T and Polisky, B (1996). A SELEX primer. Methods Enzymol 267: 275-301.
31. Green, LS, Jellinek, D, Bell, C, Beebe, LA, Feistner, BD, Gill, SC et al. (1995). Nucleaseresistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol 2: 683-695.
32. Jellinek, D, Green, LS, Bell, C, Lynott, CK, Gill, N, Vargeese, C et al. (1995). Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 34: 11363-11372.
33. Lin, Y, Qiu, Q, Gill, SC and Jayasena, SD (1994). Modified RNA sequence pools for in vitro selection. Nucleic Acids Res 22: 5229-5234.
34. Pagratis, NC, Bell, C, Chang, YF, Jennings, S, Fitzwater, T, Jellinek, D et al. (1997). Potent 2'-amino-, and 2'-fluoro-2'-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. Nat Biotechnol 15: 68-73.
35. Aurup, H, Tuschl, T, Benseler, F, Ludwig, J and Eckstein, F (1994). Oligonucleotide duplexes containing 2'-amino-2'-deoxycytidines: thermal stability and chemical reactivity. Nucleic Acids Res 22: 20-24.
36. Verheyden, JP, Wagner, D and Moffatt, JG (1971). Synthesis of some pyrimidine 2'-amino- 2'-deoxynucleosides. J Org Chem 36: 250-254.
37. Guschlbauer, W and Jankowski, K (1980). Nucleoside conformation is determined by the electronegativity of the sugar substituent. Nucleic Acids Res 8: 1421-1433.
38. Green, L, Waugh, S, Binkley, JP, Hostomska, Z, Hostomsky, Z and Tuerk, C (1995). Comprehensive chemical modification interference and nucleotide substitution analysis of an RNA pseudoknot inhibitor to HIV-1 reverse transcriptase. J Mol Biol 247: 60-68.
39. Keefe, AD and Cload, ST (2008). SELEX with modified nucleotides. Curr Opin Chem Biol 12: 448-456.
40. Manoharan, M, Akinc, A, Pandey, RK, Qin, J, Hadwiger, P, John, M et al. (2011). Unique gene-silencing and structural properties of 2'-fluoro-modified siRNAs. Angew Chem Int Ed Engl 50: 2284-2288.
41. Pallan, PS, Greene, EM, Jicman, PA, Pandey, RK, Manoharan, M, Rozners, E et al. (2011). Unexpected origins of the enhanced pairing affinity of 2'-fluoro-modified RNA. Nucleic Acids Res 39: 3482-3495.
42. Williams, DM, Benseler, F and Eckstein, F (1991). Properties of 2'-fluorothymidinecontaining oligonucleotides: interaction with restriction endonuclease EcoRV. Biochemistry 30: 4001-4009.
43. Biesecker, G, Dihel, L, Enney, K and Bendele, RA (1999). Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology 42: 219-230.
44. Ruckman, J, Green, LS, Beeson, J, Waugh, S, Gillette, WL, Henninger, DD et al. (1998). 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273: 20556-20567.
45. Rusconi, CP, Roberts, JD, Pitoc, GA, Nimjee, SM, White, RR, Quick, G Jr et al. (2004). Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 22: 1423-1428.
46. Burmeister, PE, Lewis, SD, Silva, RF, Preiss, JR, Horwitz, LR, Pendergrast, PS et al. (2005). Direct in vitro selection of a 2'-O-methyl aptamer to VEGF. Chem Biol 12: 25-33.
47. Bouchard, PR, Hutabarat, RM and Thompson, KM (2010). Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 50: 237-257.
48. Gold, L (1995). Oligonucleotides as research, diagnostic, and therapeutic agents. J Biol Chem 270: 13581-13584.
49. Gold, L, Ayers, D, Bertino, J, Bock, C, Bock, A, Brody, EN et al. (2010). Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5: e15004.
50. Binz, HK, Amstutz, P and Plückthun, A (2005). Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 23: 1257-1268.
51. Willis, MC, Hicke, BJ, Uhlenbeck, OC, Cech, TR and Koch, TH (1993). Photocrosslinking of 5-iodouracil-substituted RNA and DNA to proteins. Science 262: 1255-1257.
52. Eaton, BE, Gold, L, Hicke, BJ, Janjiæ, N, Jucker, FM, Sebesta, DP et al. (1997). Post- SELEX combinatorial optimization of aptamers. Bioorg Med Chem 5 : 1087-1096.
53. Hollenstein, M, Hipolito, CJ, Lam, CH and Perrin, DM (2009). A DNAzyme with three protein-like functional groups: enhancing catalytic efficiency of M2+-independent RNA cleavage. Chembiochem 10: 1988-1992.
54. Perrin, DM, Garestier, T and Hélène, C (1999). Expanding the catalytic repertoire of nucleic acid catalysts: simultaneous incorporation of two modified deoxyribonucleoside triphosphates bearing ammonium and imidazolyl functionalities. Nucleosides Nucleotides 18: 377-391.
55. Thomas, JM, Yoon, JK and Perrin, DM (2009). Investigation of the catalytic mechanism of a synthetic DNAzyme with protein-like functionality: an RNaseA mimic? J Am Chem Soc 131: 5648-5658.
56. Battersby, TR, Ang, DN, Burgstaller, P, Jurczyk, SC, Bowser, MT, Buchanan, DD et al. (1999). Quantitative analysis of receptors for adenosine nucleotides obtained via in vitro selection from a library incorporating a cationic nucleotide analog. J Am Chem Soc 121: 9781-9789.
57. Latham, JA, Johnson, R and Toole, JJ (1994). The application of a modified nucleotide in aptamer selection: novel thrombin aptamers containing 5-(1-pentynyl)-2'-deoxyuridine. Nucleic Acids Res 22: 2817-2822.
58. Masud, MM, Kuwahara, M, Ozaki, H and Sawai, H (2004). Sialyllactose-binding modified DNA aptamer bearing additional functionality by SELEX. Bioorg Med Chem 12: 1111-1120.
59. Ohsawa, K, Kasamatsu, T, Nagashima, J, Hanawa, K, Kuwahara, M, Ozaki, H et al. (2008). Arginine-modified DNA aptamers that show enantioselective recognition of the dicarboxylic acid moiety of glutamic acid. Anal Sci 24: 167-172.
60. Santoro, SW, Joyce, GF, Sakthivel, K, Gramatikova, S and Barbas CF 3rd (2000). RNA cleavage by a DNA enzyme with extended chemical functionality. J Am Chem Soc 122: 2433-2439.
61. Shoji, A, Kuwahara, M, Ozaki, H and Sawai, H (2007). Modified DNA aptamer that binds the ®-isomer of a thalidomide derivative with high enantioselectivity. J Am Chem Soc 129: 1456-1464.
62. Sidorov, AV, Grasby, JA and Williams, DM (2004). Sequence-specific cleavage of RNA in the absence of divalent metal ions by a DNAzyme incorporating imidazolyl and amino functionalities. Nucleic Acids Res 32: 1591-1601.
63. Tarasow, TM, Tarasow, SL and Eaton, BE (1997). RNA-catalysed carbon-carbon bond formation. Nature 389: 54-57.
64. Vaish, NK, Larralde, R, Fraley, AW, Szostak, JW and McLaughlin, LW (2003). A novel, modification-dependent ATP-binding aptamer selected from an RNA library incorporating a cationic functionality. Biochemistry 42: 8842-8851.
65. Vaught, JD, Bock, C, Carter, J, Fitzwater, T, Otis, M, Schneider, D et al. (2010). Expanding the chemistry of DNA for in vitro selection. J Am Chem Soc 132: 4141-4151.
66. Wiegand, TW, Janssen, RC and Eaton, BE (1997). Selection of RNA amide synthases. Chem Biol 4: 675-683.
67. Mehan, MR, Ostroff, R, Wilcox, SK, Steele, F, Schneider, D, Jarvis, TC et al. (2013). Highly multiplexed proteomic platform for biomarker discovery, diagnostics, and therapeutics. Adv Exp Med Biol 735: 283-300.
68. Mian, IS, Bradwell, AR and Olson, AJ (1991). Structure, function and properties of antibody binding sites. J Mol Biol 217: 133-151.
69. Ramaraj, T, Angel, T, Dratz, EA, Jesaitis, AJ and Mumey, B (2012). Antigen-antibody interface properties: composition, residue interactions, and features of 53 non-redundant structures. Biochim Biophys Acta 1824: 520-532.
70. Gold, L, Janjic, N. (1998). High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF). US Patents 5,811,533, 5,849,479.
71. Jellinek, D, Lynott, CK, Rifkin, DB and Janjić, N (1993). High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proc Natl Acad Sci USA 90: 11227-11231.
72. Gupta, S, Hirota, M, Waugh, SM, Murakami, I, Suzuki, T, Muraguchi, M et al. (2014). Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor. J Biol Chem 289 : 8706-8719.
73. Davies, DR, Gelinas, AD, Zhang, C, Rohloff, JC, Carter, JD, O'Connell, D et al. (2012). Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets. Proc Natl Acad Sci USA 109: 19971-19976.
74. Gelinas, AD, Davies, DR, Edwards, TE, Rohloff, JC, Carter, JD, Zhang, C et al. (2014). Crystal structure of interleukin-6 in complex with a modified nucleic acid ligand. J Biol Chem 289: 8720-8734.
75. Lee, KY, Kang, H, Ryu, SH, Lee, DS, Lee, JH and Kim, S (2010). Bioimaging of nucleolin aptamer-containing 5-(N-benzylcarboxyamide)-2'-deoxyuridine more capable of specific binding to targets in cancer cells. J Biomed Biotechnol 2010: 168306.
76. Kuntz, ID, Chen, K, Sharp, KA and Kollman, PA (1999). The maximal affinity of ligands. Proc Natl Acad Sci USA 96: 9997-10002.
77. Clackson, T and Wells, JA (1995). A hot spot of binding energy in a hormone-receptor interface. Science 267: 383-386.
78. Eriksson, AE, Baase, WA, Zhang, XJ, Heinz, DW, Blaber, M, Baldwin, EP et al. (1992). Response of a protein structure to cavity-creating mutations and its relation to the hydrophobic effect. Science 255: 178-183.
79. Kellis, JT Jr, Nyberg, K, Sali, D and Fersht, AR (1988). Contribution of hydrophobic interactions to protein stability. Nature 333: 784-786.
80. Gong, Q, Wang, J, Ahmad, KM, Csordas, AT, Zhou, J, Nie, J et al. (2012). Selection strategy to generate aptamer pairs that bind to distinct sites on protein targets. Anal Chem84: 5365-5371.
81. Nonaka, Y, Sode, K and Ikebukuro, K (2010). Screening and improvement of an anti-VEGF DNA aptamer. Molecules 15: 215-225.
82. Shi, H, Fan, X, Sevilimedu, A and Lis, JT (2007). RNA aptamers directed to discrete functional sites on a single protein structural domain. Proc Natl Acad Sci USA 104: 3742-3746.
83. Sosic, A, Meneghello, A, Cretaio, E and Gatto, B (2011). Human thrombin detection through a sandwich aptamer microarray: interaction analysis in solution and in solid phase. Sensors (Basel) 11: 9426-9441.
84. Xiao, SJ, Hu, PP, Wu, XD, Zou, YL, Chen, LQ, Peng, L et al. (2010). Sensitive discrimination and detection of prion disease-associated isoform with a dual-aptamer strategy by developing a sandwich structure of magnetic microparticles and quantum dots. Anal Chem 82: 9736-9742.
85. Ochsner, UA, Green, LS, Gold, L and Janjic, N (2014). Systematic selection of modified aptamer pairs for diagnostic sandwich assays. Biotechniques 56: 125-128, 130, 132.
86. Ito, T, Ueno, Y, Komatsu, Y and Matsuda, A (2003). Synthesis, thermal stability and resistance to enzymatic hydrolysis of the oligonucleotides containing 5-(N-aminohexyl) carbamoyl-2'-O-methyluridines. Nucleic Acids Res 31: 2514-2523.
87. Mazurek, M and Sowers, LC (1996). The paradoxical influence of thymine analogues on restriction endonuclease cleavage of oligodeoxynucleotides. Biochemistry 35: 11522-11528.
88. Nomura, Y, Ueno, Y and Matsuda, A (1997). Site-specific introduction of functional groups into phosphodiester oligodeoxynucleotides and their thermal stability and nucleaseresistance properties. Nucleic Acids Res 25: 2784-2791.
89. Sanghvi, YS, Hoke, GD, Freier, SM, Zounes, MC, Gonzalez, C, Cummins, L et al. (1993). Antisense oligodeoxynucleotides: synthesis, biophysical and biological evaluation of oligodeoxynucleotides containing modified pyrimidines. Nucleic Acids Res 21: 3197-3203.
90. Ueno, Y, Kumagai, I, Haginoya, N and Matsuda, A (1997). Effects of 5-(N-aminohexyl) carbamoyl-2'-deoxyuridine on endonuclease stability and the ability of oligodeoxynucleotide to activate RNase H. Nucleic Acids Res 25: 3777-3782.
91. Uhlmann, E, Peyman, A, Ryte, A, Schmidt, A and Buddecke, E (2000). Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression. Methods Enzymol 313: 268-284.
92. Rusconi, C. (2013). Modulators of coragulation factors. US Patent 8,389,489 B2.
93. Waters, EK, Genga, RM, Schwartz, MC, Nelson, JA, Schaub, RG, Olson, KA et al. (2011). Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood 117: 5514-5522.
94. Kraemer, S, Vaught, JD, Bock, C, Gold, L, Katilius, E, Keeney, TR et al. (2011). From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmerbased, streamlined multiplex proteomic assay. PLoS One 6: e26332.
95. Mehan, MR, Ayers, D, Thirstrup, D, Xiong, W, Ostroff, RM, Brody, EN et al. (2012). Protein signature of lung cancer tissues. PLoS One 7: e35157.
96. Ostroff, RM, Bigbee, WL, Franklin, W, Gold, L, Mehan, M, Miller, YE et al. (2010). Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 5: e15003.
97. Ostroff, RM, Mehan, MR, Stewart, A, Ayers, D, Brody, EN, Williams, SA et al. (2012). Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One 7: e46091.
98. Webber, J, Stone, TC, Katilius, E, Smith, BC, Gordon, B, Mason, MD et al. (2014). Proteomics analysis of cancer exosomes using a novel modified aptamer-based array (SOMAscan™) platform. Mol Cell Proteomics 13: 1050-1064.
99. Kiddle, SJ, Sattlecker, M, Proitsi, P, Simmons, A, Westman, E, Bazenet, C et al. (2014). Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis 38: 515-531.
100. De Groote, MA, Nahid, P, Jarlsberg, L, Johnson, JL, Weiner, M, Muzanyi, G et al. (2013). Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS One 8: e61002.
101. Nahid, P, Bliven-Sizemore, E, Jarlsberg, LG, De Groote, MA, Johnson, JL, Muzanyi, G et al. (2014). Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis. Tuberculosis (Edinb) 94: 187-196.
102. Baird, GS, Nelson, SK, Keeney, TR, Stewart, A, Williams, S, Kraemer, S et al. (2012). Agedependent changes in the cerebrospinal fluid proteome by slow off-rate modified aptamer array. Am J Pathol 180: 446-456.
103. Loffredo, FS, Steinhauser, ML, Jay, SM, Gannon, J, Pancoast, JR, Yalamanchi, P et al. (2013). Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 153: 828-839.
104. Cibiel, A, Pestourie, C and Ducongé, F (2012). In vivo uses of aptamers selected against cell surface biomarkers for therapy and molecular imaging. Biochimie 94: 1595-1606.
105. Gupta, S, Thirstrup, D, Jarvis, TC, Schneider, DJ, Wilcox, SK, Carter, J et al. (2011). Rapid histochemistry using slow off-rate modified aptamers with anionic competition. Appl Immunohistochem Mol Morphol 19: 273-278.
106. Romig, TS, Bell, C and Drolet, DW (1999). Aptamer affinity chromatography: combinatorial chemistry applied to protein purification. J Chromatogr B Biomed Sci Appl 731: 275-284.
107. Keefe, AD, Pai, S and Ellington, A (2010). Aptamers as therapeutics. Nat Rev Drug Discov 9: 537-550.
108. Dassie, JP and Giangrande, PH (2013). Current progress on aptamer-targeted oligonucleotide therapeutics. Ther Deliv 4: 1527-1546.
109. Zhou, J and Rossi, JJ (2014). Cell-type-specific, aptamer-functionalized agents for targeted disease therapy. Mol Ther Nucleic Acids 3: e169.
110. Eyetech Study Group. (2002). Preclinical and phase 1A clinical evaluation of an anti- VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22: 143-152.
111. Gragoudas, ES, Adamis, AP, Cunningham, ET Jr, Feinsod, M and Guyer, DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004). Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816.
112. Ng, EW, Shima, DT, Calias, P, Cunningham, ET Jr, Guyer, DR and Adamis, AP (2006). Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5: 123-132.
113. Vavalle, JP and Cohen, MG (2012). The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome. Future Cardiol 8: 371-382.
114. Regado Biosciences, Inc. A study to determine the efficacy and safety of REG1 compared to bivalirudin in patients undergoing PCI (regulate). 〈http://www.clinicaltrials.gov/ct2/show/ NCT01848106〉. (2013).
115. Ophthotech Corporation. A phase 3 safety and efficacy study of Fovista® (E10030) intravitreous administration in combination with either Avastin® or Eyelea® compared to Avastin® or Eylea® monotherapy. 〈http://clinicaltrials.gov/show/NCT01940887〉. (2013).
116. Floege, J, Ostendorf, T, Janssen, U, Burg, M, Radeke, HH, Vargeese, C et al. (1999). Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol 154: 169-179.
117. Green, LS, Jellinek, D, Jenison, R, Ostman, A, Heldin, CH and Janjic, N (1996). Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry 35: 14413-14424.
118. Köhler, G and Milstein, C (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.
119. Thistlethwaite, JR Jr, Haag, BW, Gaber, AO, Stuart, JK, Aronson, AJ, Mayes, JT et al. (1987). The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporine. Transplant Proc 19(1 Pt 3): 1901-1904.
120. Beck, A, Wurch, T, Bailly, C and Corvaia, N (2010). Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10: 345-352.
121. Winter, G and Milstein, C (1991). Man-made antibodies. Nature 349: 293-299.
122. Barciszewski, J, Medgaard, M, Koch, T, Kurreck, J and Erdmann, VA (2009). Locked nucleic acid aptamers. Methods Mol Biol 535: 165-186.
123. Schmidt, KS, Borkowski, S, Kurreck, J, Stephens, AW, Bald, R, Hecht, M et al. (2004). Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res 32: 5757-5765.
124. Klussmann, S, Nolte, A, Bald, R, Erdmann, VA and Fürste, JP (1996). Mirror-image RNA that binds D-adenosine. Nat Biotechnol 14: 1112-1115.
125. Pinheiro, VB, Taylor, AI, Cozens, C, Abramov, M, Renders, M, Zhang, S et al. (2012). Synthetic genetic polymers capable of heredity and evolution. Science 336: 341-344.
126. Sanghvi, YS (2011). A status update of modified oligonucleotides for chemotherapeutics applications. Curr Protoc Nucleic Acid Chem Chapter 4: Unit 4.1.1-Unit 4.122.
127. Kimoto, M, Yamashige, R, Matsunaga, K, Yokoyama, S and Hirao, I (2013). Generation of high-affinity DNA aptamers using an expanded genetic alphabet. Nat Biotechnol 31: 453-457.
128. Krissinel, E and Henrick, K (2007). Inference of macromolecular assemblies from crystalline state. J Mol Biol 372: 774-797.
129. DeLano, WL. (2002) The PyMOL Molecular Graphics System. DeLano Scientific LLC: San Carlos, CA. 〈http://www.pymol.org〉.
130. Leontis, NB and Westhof, E (2001). Geometric nomenclature and classification of RNA base pairs. RNA 7: 499-512.